Charles River Labs (CRL) has singled out China as an area of “disproportionate growth” in biologics R&D and says it is on the hunt for preclinical acquisitions in the region.
Half of drug discovery will eventually be outsourced as the service area goes the way of contract toxicology, according to the CEO of Charles River Laboratories (CRL).
Early phase CRO (contract research organization) Charles River Laboratories will lay off between 26 and 30 employees following the US National Cancer Institute’s decision to terminate a contract in which the company supplied rodent models for cancer research.
AMRI has added protein expression and purification services to its drug discovery services citing the shift in pipelines towards larger molecule drugs as a driver.
Ohio-based CRO (contract research organization) Ricerca Biosciences is holding “ongoing discussions with several parties” about the possible sale of one or more of its divisions or the entire company, CEO Tim Derrington told us.
Increasing the predictivity of in vitro systems could cut the costs of drug development and shift preclinical research away from animal models, according to Crown Bioscience.
European organisations representing academic CROs and nuclear medicine researchers have established an accreditation programme for a novel Zirconium-PET imaging technique, used in early development of monoclonal antibodies.
Drug developers should add their early-stage discoveries to an open-source database or pay a fine to cut wasted time duplicating results, say researchers.
News of the discontinuation of the National Cancer Institute’s (NCI) Animal Production Program has led Charles River Laboratories rival Harlan to vie for the market of grantees that still need animal research models.
A 3D printed human liver system could offer better informed risk-based decisions earlier in the drug development process than with current in vitro models, according to developers Organovo.
Horizon Discovery says the gene editing tool CRISPR used to engineer its human cell lines is exploding the possibilities of screening for preclinical customers.
Evotec has partnered with Shire to develop inhibitors against Fabry’s disease and says such collaborations will grow as Big Pharma increasingly looks towards rare diseases.
Charles River Laboratories is approaching its optimal capacity utilisation but says pricing will not improve until the rest of the preclinical CRO industry follows suit.
US demand for biosimilar preclinical services is expected to rocket on the back of the US FDA’s acceptance of Sandoz’s biosimilar filing, according to Harlan Laboratories.
The tightening federal budget is increasing competition between research institutes and academia when it comes to preclinical toxicology testing, according to MRIGlobal.
SRI International was awarded a seven-year, $49m contract from the NIAID (National Institute of Allergy and Infectious Diseases), which is a division of the NIH (National Institutes of Health), for preclinical HIV/AIDS work.
Philanthropist Ted Stanley has gifted $650m to the Broad Institute as part of a wider attempt to galvanize research on psychiatric disorders and bring new treatments to market.
Preclinical CRO Harlan Laboratories has partnered with French CRO Fluofarma to strengthen the companies’ drug discovery and translational medicine services.
Pharma services firm Peakdale Molecular has joined with two UK environmental testing providers to form Concept Life Sciences in a private-equity backed agreement.
The Center for Responsible Science has asked the US FDA to adopt informed consent rules which ensure that trial participants know the experimental drugs they receive may be unsafe or ineffective.
Lonza has launched a new stem cell reprogramming and maintenance system that has already been used to support US NIH and pharmaceutical company preclinical drug development projects.
The ability to pinpoint radiotherapy in animal testing could give failed cancer drug candidates a new lease of life, says preclinical CRO (contract research organisation) Crown Biosciences.
Sounding upbeat on Covance’s recent gains in its early stage clinical business, CFO Alison Cornell expressed a conservative amount of optimism that growth will continue.
A few months after announcing its arrival in South Korea, Celerion and the Korean Drug Development Fund (KDDF) have agreed to collaborate to provide drug development expertise and support for the emerging industry.
Evotec has acquired all shares in UK-based specialist CRO Euprotec for as much as $5.26m to add anti-infective drug discovery services to its offerings.
Crown Biosciences has partnered with China’s biggest producer of mutant mice to build better experimental models for its cancer research sponsors, as part of its $26.5m (£16m) venture funding.
Contract research organisations Covance, Harlan, Sequani, Charles River Laboratories and Huntingdon Life Sciences have signed an agreement to be open about their animal research.
Huntingdon Life Sciences has acquired contract research and animal models firm Harlan Laboratories, making it the third largest preclinical research organisation, according to the company.
Bayer has inked a deal with preclinical CRO Cenix BioScience to use its genome-scale RNA interference (RNAi) platform to target an undisclosed disease.
Biopharma is ramping up the outsourcing of some of the easier tests while tasks such as downstream process development and QbD services are being outsourced less, according to a new survey.
Toxicology services provider Harlan Laboratories has selected Invenium Pharmacology as its exclusive agent for Harlan’s Contract Research Services (CRS) in Australia, Southeast Asia and New Zealand.
AMRI says its long-term outlook remains positive with continued demand for its contract research services despite plans to shutter a Discovery and Development Services facility.
CRO Evotec AG will help Debiopharm identify and develop novel compounds with the potential to treat multiple forms of solid tumours and leukaemias with defined genetic alterations under a collabortation announced today.
Demand from biotech firms and Big Pharma’s need to refill its pipeline is driving the preclinical services industry, say analysts at this year’s Society of Toxicology (SOT) meeting.
BioReliance has updated its big blue assay for the second time in six months by creating a version of the drug genotoxicity test that can be used in rats.
GSK has asked Formula One team Mclaren to help it discover drugs, arguing that Big Data expertise from outside the contract research sector can accelerate its efforts to develop new blockbuster meds.
Covance has announced that its recently expanded large molecule bioanalytical space at its laboratory facility in Indianapolis will come online in late 2014.
Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations to the attention of pharma and biopharma sponsors.
Pharmaceutical companies need to change their attitudes to contractors, says the former director of Shire’s relationships with its 100 outsourcing partners.
Harlan is looking to take advantage of a dearth of new products in pharma clients’ pipelines with an early drug development partnership with France’s Bertin Pharma.
Clinical research group Venn Life Sciences has acquired the rights to LabSkin (pictured), a human skin substitute that behaves like the real thing, from dermatology CRO Evocutis.
